Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 9:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,035 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo Sugar Pill Clear all
Completed Not applicable Interventional Results available

Mifepristone Treatment for Patients With Non-psychotic Major Depressive Disorder Receiving Bilateral ECT

NCT00285818
View directory record Official record
Conditions
Depression
Interventions
Mifepristone, Placebo Oral Capsule
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Sep 17, 2026, 9:32 AM EDT
Terminated Phase 2 Interventional

An Evaluation of the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia

NCT00412620
View directory record Official record
Conditions
Schizophrenia
Interventions
ABT-925, Placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
11
States / cities
Anaheim, California • Cerritos, California • Garden Grove, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2011 · Synced Sep 17, 2026, 9:32 AM EDT
Completed Phase 2 Interventional Results available

Naltrexone in the Treatment of Trichotillomania

NCT00775229
View directory record Official record
Conditions
Trichotillomania
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Sep 17, 2026, 9:32 AM EDT
Completed Phase 2 Interventional Results available

Enhancing the Effects of Adolescent Alcohol Treatment With Atomoxetine

NCT04565288
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Brown University
Other
Eligibility
14 Years to 20 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Sep 17, 2026, 9:32 AM EDT
Completed Not applicable Interventional Results available

Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant

NCT00248547
View directory record Official record
Conditions
Cancer
Interventions
aprepitant, dexamethasone, ondansetron, placebo
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 17, 2026, 9:32 AM EDT
Completed Early Phase 1 Interventional

Assess Efficacy of of Oral Treprostinil in Patients With Symptomatic Primary or Secondary Raynaud's Phenomenon

NCT02583789
View directory record Official record
Conditions
Raynaud's Phenomenon
Interventions
oral treprostinil, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 9, 2022 · Synced Sep 17, 2026, 9:32 AM EDT
Not listed Phase 4 Interventional

Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study)

NCT00794625
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Valproate, Risperidone, Placebo, Stimulant medication, Behavioral family counseling
Drug · Behavioral
Lead sponsor
Joseph Blader
NIH
Eligibility
6 Years to 12 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Glen Oaks, New York • Stony Brook, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2012 · Synced Sep 17, 2026, 9:32 AM EDT
Completed Phase 2 Interventional Results available

HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) for the Treatment of Alcohol Use Disorder

NCT02252536
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
gabapentin enacarbil, Placebo
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years and older
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Sep 17, 2026, 9:32 AM EDT
Withdrawn Phase 3 Interventional

Vitamin D Status in Patients With Severe Sepsis

NCT02684487
View directory record Official record
Conditions
Sepsis, Severe Sepsis, End Organ Damage, Multi Organ Failure
Interventions
vitamin D3, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Sep 17, 2026, 9:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Mibefradil When Given Four Times a Day in Healthy Volunteers

NCT01550458
View directory record Official record
Conditions
Healthy
Interventions
mibefradil, Placebo
Drug · Other
Lead sponsor
Cavion, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 7, 2019 · Synced Sep 17, 2026, 9:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Escitalopram Effects on CSF Amyloid Beta

NCT02161458
View directory record Official record
Conditions
Amyloid Beta Protein
Interventions
Escitalopram 20mg for 2 weeks, Escitalopram 20mg for 8 weeks, Escitalopram 30mg for 8 weeks, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
60 Years to 85 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
2
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Sep 17, 2026, 9:32 AM EDT
Completed Phase 2 Interventional Results available

Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies

NCT04002674
View directory record Official record
Conditions
Dementia With Lewy Bodies
Interventions
Placebo oral capsule, Nilotinib Oral Capsule
Drug
Lead sponsor
Georgetown University
Other
Eligibility
25 Years to 90 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 17, 2026, 9:32 AM EDT
Completed Phase 2 Interventional

Efficacy Study of VA106483 in Males With Nocturia.

NCT01038843
View directory record Official record
Conditions
Nocturia
Interventions
VA106483
Drug
Lead sponsor
Vantia Ltd
Industry
Eligibility
18 Years and older · Male only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
19
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Sep 17, 2026, 9:32 AM EDT
Withdrawn Phase 4 Interventional

Ramelteon vs Placebo for Prevention of Delirium and Improvement of Sleep in Hospitalized Older Adults

NCT03165695
View directory record Official record
Conditions
Delirium in Old Age
Interventions
Ramelteon, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
65 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Sep 17, 2026, 9:32 AM EDT
Completed Phase 4 Interventional Results available

Studying the Effects of Phentermine on Eating Behavior

NCT01886937
View directory record Official record
Conditions
Obesity
Interventions
Phentermine, placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2017 · Synced Sep 17, 2026, 9:32 AM EDT
Completed Phase 4 Interventional

Quetiapine Compared With Placebo in the Management of Fibromyalgia

NCT01458964
View directory record Official record
Conditions
Fibromyalgia
Interventions
Quetiapine
Drug
Lead sponsor
East Tennessee State University
Other
Eligibility
18 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Johnson City, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 8, 2014 · Synced Sep 17, 2026, 9:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Cognitive Enhancing Effects of D-Cycloserine Among Non-Demented Elderly

NCT01361633
View directory record Official record
Conditions
Treatment, Placebo
Interventions
d-cycloserine, Sugar Pill
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
60 Years and older
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 17, 2026, 9:32 AM EDT
Terminated Phase 2 Interventional Results available

Minocycline for Postsurgical Symptom Reduction in Head and Neck Cancer

NCT02055963
View directory record Official record
Conditions
Head And Neck Cancer
Interventions
Minocycline, Placebo, Questionnaires
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Sep 17, 2026, 9:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD)

NCT01172652
View directory record Official record
Conditions
Bipolar Disorder, Panic Disorder, Generalized Anxiety Disorder
Interventions
Ziprasidone, Placebo
Drug
Lead sponsor
VA Palo Alto Health Care System
Federal
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
3
States / cities
Palo Alto, California • Tampa, Florida • Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Sep 17, 2026, 9:32 AM EDT
Completed Early Phase 1 Interventional Results available

D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder

NCT00842309
View directory record Official record
Conditions
Body Dysmorphic Disorder
Interventions
d-cycloserine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 17, 2019 · Synced Sep 17, 2026, 9:32 AM EDT
Completed Phase 1 Interventional

Investigation of Cycloserine as a Smoking Cessation Treatment

NCT01062932
View directory record Official record
Conditions
Nicotine Addiction
Interventions
Cycloserine, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2012 · Synced Sep 17, 2026, 9:32 AM EDT
Completed Not applicable Interventional Results available

Evaluation of Lamotrigine on Neuropathic Facial Pain Using fMRI

NCT00243152
View directory record Official record
Conditions
Facial Neuropathy
Interventions
Lamotrigine, Placebo (for Lamotrigine)
Drug
Lead sponsor
Pain and Analgesia Imaging and Neuroscience Group
Other
Eligibility
18 Years to 60 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Sep 17, 2026, 9:32 AM EDT
Completed Phase 2 Interventional Results available

Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis

NCT00854087
View directory record Official record
Conditions
Chronic Hepatitis C Infection
Interventions
Fuzheng Huayu, Placebo
Drug
Lead sponsor
Tarek Hassanein
Individual
Eligibility
18 Years to 70 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Coronado, California • Palo Alto, California • Pasadena, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Sep 17, 2026, 9:32 AM EDT
Completed Not applicable Interventional Results available

Doxycycline for COPD in HIV-Infected Patients

NCT01744093
View directory record Official record
Conditions
HIV, Chronic Obstructive Pulmonary Disease (COPD), Emphysema
Interventions
Doxycycline, Placebo (sugar pill)
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 85 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Sep 17, 2026, 9:32 AM EDT